AR114827A1 - Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida - Google Patents
Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamidaInfo
- Publication number
- AR114827A1 AR114827A1 ARP190101056A ARP190101056A AR114827A1 AR 114827 A1 AR114827 A1 AR 114827A1 AR P190101056 A ARP190101056 A AR P190101056A AR P190101056 A ARP190101056 A AR P190101056A AR 114827 A1 AR114827 A1 AR 114827A1
- Authority
- AR
- Argentina
- Prior art keywords
- indacen
- sodium salt
- sulfonamida
- hexahidro
- isopropil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Una sal sódica de N-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1H-pirazol-3-sulfonamida o un hidrato o solvato de esta. Reivindicación 5: La sal de cualquiera de las reivindicaciones de 1 a 4, en donde la sal es una sal monosódica cristalina de monohidrato de N-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1H-pirazol-3-sulfonamida. Reivindicación 6: Una forma polimórfica de la sal de la reivindicación 5 que tiene un espectro de XRPD que comprende picos a aproximadamente: 4,3 º2q, 8,7 º2q y 20,6 º2q.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1806578.9A GB201806578D0 (en) | 2018-04-23 | 2018-04-23 | Novel compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114827A1 true AR114827A1 (es) | 2020-10-21 |
Family
ID=62236309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101056A AR114827A1 (es) | 2018-04-23 | 2019-04-23 | Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10973803B2 (es) |
| EP (2) | EP3722281A1 (es) |
| JP (1) | JP7382958B2 (es) |
| KR (1) | KR20210005589A (es) |
| CN (1) | CN112020495B (es) |
| AR (1) | AR114827A1 (es) |
| AU (1) | AU2019257973A1 (es) |
| BR (1) | BR112020021650A2 (es) |
| CA (1) | CA3097832A1 (es) |
| CY (1) | CY1123260T1 (es) |
| DK (1) | DK3606909T3 (es) |
| ES (1) | ES2811228T3 (es) |
| GB (1) | GB201806578D0 (es) |
| HR (1) | HRP20201263T1 (es) |
| HU (1) | HUE050369T2 (es) |
| LT (1) | LT3606909T (es) |
| MA (2) | MA48051B1 (es) |
| MD (1) | MD3606909T2 (es) |
| ME (1) | ME03822B (es) |
| MX (1) | MX2020011196A (es) |
| PL (1) | PL3606909T3 (es) |
| PT (1) | PT3606909T (es) |
| RS (1) | RS60646B1 (es) |
| SI (1) | SI3606909T1 (es) |
| TW (1) | TW201943704A (es) |
| UY (1) | UY38186A (es) |
| WO (1) | WO2019206871A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201837021A (zh) | 2017-01-23 | 2018-10-16 | 美商傑庫爾醫療股份有限公司 | 作為介白素-1活性抑制劑之化合物 |
| US11840543B2 (en) | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| AU2018317798A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| KR20200041337A (ko) | 2017-08-15 | 2020-04-21 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| EP3707134A1 (en) | 2017-11-09 | 2020-09-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019166628A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| US11530200B2 (en) | 2018-03-02 | 2022-12-20 | Inflazome Limited | Compounds |
| EP3759090A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2019166627A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| CA3104199A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| JP2023500925A (ja) * | 2019-11-07 | 2023-01-11 | インフレイゾーム リミテッド | 神経炎症または炎症性脳疾患の処置および予防 |
| WO2021089781A1 (en) * | 2019-11-07 | 2021-05-14 | Inflazome Limited | Treatment or prevention of psychiatric brain disorders using the nlrp3 inhibitor n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide |
| GB201916237D0 (en) * | 2019-11-07 | 2019-12-25 | Inflazome Ltd | Novel treatment |
| CN114641287A (zh) * | 2019-11-07 | 2022-06-17 | 英夫拉索姆有限公司 | 神经退行性病症的治疗和预防 |
| EP4054564A1 (en) * | 2019-11-07 | 2022-09-14 | Inflazome Limited | Treatment of autoinflammatory disorders |
| WO2021089776A1 (en) * | 2019-11-07 | 2021-05-14 | Inflazome Limited | Treatment and prevention of a traumatic brain disorder |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4802908A (en) * | 1987-01-22 | 1989-02-07 | E. I. Du Pont De Nemours And Company | Herbicidal 2-(1H)-pyrazinones |
| EP1214087A1 (en) * | 1999-09-14 | 2002-06-19 | Pfizer Products Inc. | Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| JPWO2013031931A1 (ja) * | 2011-09-02 | 2015-03-23 | 協和発酵キリン株式会社 | ケモカイン受容体活性調節剤 |
| MD3259253T2 (ro) | 2015-02-16 | 2020-06-30 | Univ Queensland | Sulfoniluree și compuși înrudiți și utilizări ale acestora |
| FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| JP2019512009A (ja) | 2016-02-16 | 2019-05-09 | ザ・ユニバーシティ・オブ・クイーンズランド | スルホニルウレアおよび関連化合物ならびにこれらの利用 |
| MA44729A (fr) | 2016-04-18 | 2021-05-12 | Novartis Ag | Composés et compositions pour traiter des états associés à une activité de nlrp |
| WO2017184604A1 (en) | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
| EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
-
2018
- 2018-04-23 GB GBGB1806578.9A patent/GB201806578D0/en not_active Ceased
-
2019
- 2019-04-23 SI SI201930005T patent/SI3606909T1/sl unknown
- 2019-04-23 AR ARP190101056A patent/AR114827A1/es unknown
- 2019-04-23 MX MX2020011196A patent/MX2020011196A/es unknown
- 2019-04-23 CA CA3097832A patent/CA3097832A1/en active Pending
- 2019-04-23 JP JP2020557902A patent/JP7382958B2/ja active Active
- 2019-04-23 WO PCT/EP2019/060311 patent/WO2019206871A1/en unknown
- 2019-04-23 ES ES19721230T patent/ES2811228T3/es active Active
- 2019-04-23 TW TW108114167A patent/TW201943704A/zh unknown
- 2019-04-23 EP EP20176198.8A patent/EP3722281A1/en not_active Withdrawn
- 2019-04-23 MD MDE20200181T patent/MD3606909T2/ro unknown
- 2019-04-23 PT PT197212301T patent/PT3606909T/pt unknown
- 2019-04-23 ME MEP-2020-173A patent/ME03822B/me unknown
- 2019-04-23 CN CN201980026640.0A patent/CN112020495B/zh active Active
- 2019-04-23 MA MA48051A patent/MA48051B1/fr unknown
- 2019-04-23 BR BR112020021650-0A patent/BR112020021650A2/pt not_active Application Discontinuation
- 2019-04-23 MA MA051082A patent/MA51082A/fr unknown
- 2019-04-23 HU HUE19721230A patent/HUE050369T2/hu unknown
- 2019-04-23 RS RS20200936A patent/RS60646B1/sr unknown
- 2019-04-23 LT LTEP19721230.1T patent/LT3606909T/lt unknown
- 2019-04-23 EP EP19721230.1A patent/EP3606909B1/en active Active
- 2019-04-23 KR KR1020207030023A patent/KR20210005589A/ko not_active Application Discontinuation
- 2019-04-23 AU AU2019257973A patent/AU2019257973A1/en not_active Abandoned
- 2019-04-23 UY UY0001038186A patent/UY38186A/es not_active Application Discontinuation
- 2019-04-23 DK DK19721230.1T patent/DK3606909T3/da active
- 2019-04-23 PL PL19721230T patent/PL3606909T3/pl unknown
-
2020
- 2020-04-16 US US16/850,978 patent/US10973803B2/en active Active
- 2020-08-11 HR HRP20201263TT patent/HRP20201263T1/hr unknown
- 2020-08-12 CY CY20201100756T patent/CY1123260T1/el unknown
-
2021
- 2021-03-09 US US17/196,956 patent/US20210315862A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210005589A (ko) | 2021-01-14 |
| CN112020495B (zh) | 2024-05-17 |
| DK3606909T3 (da) | 2020-08-24 |
| MD3606909T2 (ro) | 2020-08-31 |
| EP3606909A1 (en) | 2020-02-12 |
| EP3722281A1 (en) | 2020-10-14 |
| US20210315862A1 (en) | 2021-10-14 |
| TW201943704A (zh) | 2019-11-16 |
| PL3606909T3 (pl) | 2020-11-16 |
| MA48051B1 (fr) | 2020-08-31 |
| AU2019257973A1 (en) | 2020-11-19 |
| UY38186A (es) | 2019-11-29 |
| JP2021522195A (ja) | 2021-08-30 |
| US10973803B2 (en) | 2021-04-13 |
| MA51082A (fr) | 2021-05-19 |
| CN112020495A (zh) | 2020-12-01 |
| BR112020021650A2 (pt) | 2021-01-26 |
| HRP20201263T1 (hr) | 2021-02-05 |
| LT3606909T (lt) | 2020-10-12 |
| GB201806578D0 (en) | 2018-06-06 |
| ME03822B (me) | 2021-04-20 |
| EP3606909B1 (en) | 2020-05-27 |
| ES2811228T3 (es) | 2021-03-11 |
| SI3606909T1 (sl) | 2020-09-30 |
| HUE050369T2 (hu) | 2020-11-30 |
| RS60646B1 (sr) | 2020-09-30 |
| US20200237723A1 (en) | 2020-07-30 |
| WO2019206871A1 (en) | 2019-10-31 |
| JP7382958B2 (ja) | 2023-11-17 |
| CA3097832A1 (en) | 2019-10-31 |
| MX2020011196A (es) | 2020-11-13 |
| PT3606909T (pt) | 2020-07-09 |
| CY1123260T1 (el) | 2021-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114827A1 (es) | Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| CY1120705T1 (el) | Καινοφανεις αναστολεις αποακετυλασων ιστονων | |
| EA201892128A1 (ru) | Гетероциклические амиды, полезные в качестве модуляторов | |
| EA201992235A1 (ru) | Синтез ингибитора mcl-1 | |
| EA201792021A1 (ru) | Ингибитор jak | |
| ECSP17054980A (es) | Inhibidores selectivos de bace1 | |
| AR112276A1 (es) | Polimorfos de 5-fluoro-4-imino-3-metil-1-tosil-3,4-dihidropirimidin-2-ona | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| CL2021000426A1 (es) | Inhibidores de la interacción proteína-proteína keap1-nrf2. | |
| AR110768A1 (es) | Formas cristalinas de tenofovir alafenamida | |
| EA201690911A1 (ru) | Соединения диметилбензойной кислоты | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| AR105967A1 (es) | Sales de un inhibidor de pim quinasa | |
| CA2914620C (en) | Heterocyclic derivatives and use thereof | |
| EA201592183A1 (ru) | Ингибиторы bace | |
| EA201591915A1 (ru) | Соединения феноксиэтил дигидро-1h-изохинолина | |
| CO2020001471A2 (es) | Compuesto pentacíclico | |
| EA201990238A1 (ru) | ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC | |
| CL2019001804A1 (es) | Activador de nrf2. | |
| EA202191051A1 (ru) | Ингибитор аврора-киназы a для применения для лечения нейробластомы | |
| EA201991241A1 (ru) | Способ получения метоксиметилпиридин дикарбоксилата | |
| EA201990952A1 (ru) | ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met | |
| AR114270A1 (es) | Compuestos de 4-metildihidropirimidinona y su uso farmacéutico | |
| MD3504208T2 (ro) | Derivat de triazolopirazinonă util în calitate de inhibitor al PDE1 uman |